[1] Fei X, Han P, Jiang B,et al. High frame rate contrast-enhanced ultrasound helps differentiate malignant and benign focal liver lesions. J Clin Transl Hepatol, 2022,10(1):26-33. [2] Srivastava A, Prasad D, Panda I,et al. Transjugular versus percutaneous liver biopsy in children: indication, success, yield, and complications. J Pediatr Gastroenterol Nutr, 2020,70(4):417-422. [3] XuR, Wang J, Huang X, et al. Clinical value of spectral CT imaging combined with AFP in identifying liver cancer and hepatic focal nodular hyperplasia. J BUON, 2019,24(4):1429-1434. [4] Fang L, Huang BJ, Ding H,et al. Contrast-enhanced ultrasound (CEUS) for the diagnosis of hypoechoic hepatic hemangioma in clinical practice. Clin Hemorheol Microcirc, 2019,72(4):395-405. [5] Mori N, Mugikura S, Miyashita M,et al. Perfusion contrast-enhanced ultrasound to predict early lymph-node metastasis in breast cancer. Jpn J Radiol, 2019,37(2):145-153. [6] Gu F, Han L, Yang X,et al. Value of time-intensity curve analysis of contrast-enhanced ultrasound in the differential diagnosis of thyroid nodules. Eur J Radiol, 2018,105(1):182-187. [7] 中国抗癌协会肝癌专业委员会.中国肝癌多学科综合治疗专家共识.临床肝胆病杂志,2021,37(2):278-285. [8] 《原发性肝癌诊疗规范(年版)》编写专家委员会.PLC诊疗规范(2019年版).中国临床医学,2020,27(1):140-156. [9] Xu L, Yang X, Ke S,et al. Resection as first-line therapy for large hepatic sclerosing hemangioma: a case report. Onco Targets Ther, 2019,12(1):6839-6842. [10] Tang B, Zhu J, Zhao Z, et al. Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden. J Adv Res, 2021,33(1):153-165. [11] Peng JB, Peng YT, Lin P,et al. Differentiation infected focal liver lesions from malignant mimickers: value of ultrasound-based radiomics. Clin Radiol, 2022,77(2):104-113. [12] Dong Y, Chen S, Möller K,et al. Applications of dynamic contrast-enhanced ultrasound in differential diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in non-cirrhotic liver. Ultrasound Med Biol, 2023,6(23):127-130. [13] Chen W, Peng J, Ye J,et al. Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis. J Cancer, 2020,11(2):403-413. [14] ChenT, Dai X, Dai J, et al. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis, 2020,11(10):822. [15] Wang S, Zhu M, Wang Q,et al. Alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling. Cell Death Dis, 2018,9(10):1027. [16] Edoo MIA, Chutturghoon VK, Wusu-Ansah GK,et al. Serum biomarkers AFP, CEA and ca19-9 combined detection for early diagnosis of hepatocellular carcinoma. Iran J Public Health, 2019,48(2):314-322. [17] 方茜,李韦杰,郭晶晶,等.血清AFP和PIVKA-Ⅱ的检测对肝炎病毒相关HCC的诊断价值.标记免疫分析与临床,2022,29(9):1441-1445. [18] Huang Z, Wu X, Li S,et al. Contrast-enhanced ultrasound findings and differential diagnosis of hepatic epithelioid angiomyolipoma compared with hepatocellular carcinoma. Ultrasound Med Biol, 2020,46(6):1403-1411. [19] Schaible J, Stroszczynski C, Beyer LP,et al. Quantitative perfusion analysis of hepatocellular carcinoma using dynamic contrast enhanced ultrasound (CEUS) to determine tumor microvascularization. Clin Hemorheol Microcirc, 2019,73(1):95-104. [20] Dong Y, Qiu Y, Yang D,et al. Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma. Clin Hemorheol Microcirc, 2021,77(4):461-469. [21] Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol, 2020,10(1):1316. [22] 韩鹏伟,王虎明,赵天永.AFP阴性原发性肝癌临床特征及预后因素分析.实用肝脏病杂志,2020,23(5):715-718. [23] Liu Z, Pu Y, Bao Y,et al. Investigation of potential molecular biomarkers for diagnosis and prognosis of AFP-negative HCC. Int J Gen Med, 2021,14(1):4369-4380. |